Immune Pharmaceuticals Inc. (IMNP)

Oncology Corporate Profile

Stock Performance

0.4003
-0.0276

3 Month Stock History Chart

HQ Location

777 Old Saw Mill River Road
Tarrytown, NY 10591

Company Description

Immune Pharmaceuticals Inc.applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn's disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company's growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Website: http://immunepharmaceuticals.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Ceplene® / histamine dihydrochloridehistamine H2 receptor agonistAcute Myelogenous Leukemia (AML)III
Azixa® / MPC-6827vascular disrupting agentGlioblastoma Multiforme (GBM)II
Crolibulin® / EPC2407vascular disrupting agentAnaplastic Thyroid cancerI
Crolibulin® / EPC2407vascular disrupting agentVarious cancer typesI
EP128504apoptosis inducerBreast cancerPreclinical
EP128504apoptosis inducerColorectal cancerPreclinical
EP192112apoptosis inducerVarious cancer typesPreclinical
EP2167apoptosis inducerVarious cancer typesPreclinical

View additional information on product candidates here »

Source: http://immunepharmaceuticals.com/

Recent News Headlines

There are no news items to display